<PAGE>

================================================================================

                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                            ----------------------

                                     2000
                                  FORM 10 - Q

                                For the Fiscal
                                 FIRST QUARTER
                              Ended April 1, 2000

                Quarterly Report Pursuant To Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                               MOORE MEDICAL CORP.
             (Exact name of registrant as specified in its charter)
--------------------------------------------------------------------------------

Delaware                                                1-8903
(State of incorporation)                                (Commission File Number)

P.O. Box 1500, New Britain, CT  06050                   22-1897821
(Address of principal executive offices)                (I.R.S. Employer
                                                        Identification Number)

860-826-3600
(Registrant's telephone number)

           Securities registered pursuant to Section 12(b) of the Act:

Common Stock ($.01 Par Value)                            American Stock Exchange
Rights to Purchase Series I Junior                       American Stock Exchange
 Preferred Stock
(Title of Each Class)                (Name of each exchange on which registered)
--------------------------------------------------------------------------------

     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding twelve months, and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No
                                   ------- -------

   Approximately 3,045,176 number of shares of Common Stock outstanding as of
                                 April 28, 2000

              Total number of pages in the numbered original is 59

                           This is page 1 of 59 pages.
================================================================================
<PAGE>

                               MOORE MEDICAL CORP.


                                      Index


<TABLE>
<CAPTION>
                                                                                                 Page No.
                                                                                                 --------
<S>        <C>                                                                                   <C>
Part I.    Financial Information

           Item 1.    Financial Statements

                      Balance Sheets at the end of the first quarter of
                           2000 and at the end of the year 1999......................                   3

                      Statements of Operations for the first quarters
                           of 2000 and 1999..........................................                   4

                      Statements of Cash Flows for the first quarters
                           of 2000 and 1999..........................................                   5

                      Notes to Financial Statements..................................                  6-7

           Item 2.    Management's Discussion and Analysis of Financial
                           Condition and Results of Operations.......................                  8-11

           Item 3.    Quantitative and Qualitative Disclosures About
                           Market Risk...............................................                   11

Part II.   Other Information

           Item 5.   Other Matters...................................................                   12

           Item 6.    Exhibits and Reports on Form 8-K...............................                 12-59

           Signatures................................................................                   13
</TABLE>

                                       2
<PAGE>

                               MOORE MEDICAL CORP.

<TABLE>
<CAPTION>
                                                          Balance Sheets
------------------------------------------------------------------------------------------------------------------------------------
(Amounts in thousands, except par value)                               First Quarter 2000             Year 1999
                                                                           (Unaudited)
------------------------------------------------------------------------------------------------------------------------------------

<S>                                                                          <C>                      <C>
ASSETS

Current Assets
       Cash                                                                  $  6,572                  $    744
       Accounts receivable, less allowances
           of $200 and $200.......................................             12,255                    11,488
       Inventories................................................             11,185                    14,242
       Prepaid expenses and other current assets..................              3,050                     1,852
       Deferred income taxes......................................              2,330                     2,330
                                                                             --------                  --------
                Total Current Assets..............................             35,392                    30,656
                                                                             --------                  --------

Noncurrent Assets
       Equipment and leasehold improvements, net.                              10,327                    10,641
       Other assets...............................................                370                       669
                                                                             --------                  --------
                Total Noncurrent Assets...........................             10,697                    11,310
                                                                             --------                  --------
                                                                             $ 46,089                  $ 41,966
                                                                             ========                  ========

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
       Accounts payable...........................................           $ 10,491                  $  7,483
       Accrued expenses...........................................              5,035                     4,665
                                                                             --------                  --------
                Total Current Liabilities.........................             15,526                    12,148
                                                                             --------                  --------

Deferred Income Taxes.............................................              2,368                     2,368

Shareholders' Equity
       Preferred stock - no shares outstanding....................                 --                        --
       Common stock - $.01 par value;
           5,000 shares authorized;
           3,246 shares issued....................................                 34                        33
       Capital in excess of par value.............................             21,784                    21,675
       Retained earnings..........................................              8,194                     8,449
                                                                             --------                  --------
                                                                               30,012                    30,157
       Less treasury shares, at cost, 205 and 305
           shares.................................................             (1,817)                   (2,707)
                                                                             --------                  --------
                Total Shareholders' Equity........................             28,195                    27,450
                                                                             --------                  --------
                                                                             $ 46,089                  $ 41,966
                                                                             ========                  ========
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of the financial statements.

                                       3
<PAGE>

                               MOORE MEDICAL CORP.
<TABLE>
<CAPTION>
                                                     Statements of Operations
------------------------------------------------------------------------------------------------------------------------------------
(Amounts in thousands, except per share data)                                            First Quarter
                                                                             --------------------------------------
                                                                              2000                      1999
                                                                                        (Unaudited)
------------------------------------------------------------------------------------------------------------------------------------
       <S>                                                                    <C>                       <C>

       Net sales.........................................................     $29,517                   $29,055

       Cost of products sold.............................................      20,844                    19,546
                                                                             --------                   -------

       Gross profit......................................................       8,673                     9,509

       Selling, general & administrative expenses........................       9,105                     8,803
                                                                             --------                   -------

       Operating (loss) income...........................................        (432)                      706

       Interest (income), net............................................         (27)                      (45)
                                                                             --------                   -------

       (Loss) income before income taxes.................................        (405)                      751

       Income tax (benefit) provision....................................        (150)                      274
                                                                             --------                   -------

       Net (loss) income.................................................    $   (255)                  $   477
                                                                             ========                   =======

       Basic and diluted net (loss) income
           per share.....................................................    $   (.09)                  $   .16
                                                                             ========                   =======

------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of the financial statements.

                                       4
<PAGE>

                               MOORE MEDICAL CORP.
<TABLE>
<CAPTION>
                                                     Statements of Cash Flows
------------------------------------------------------------------------------------------------------------------------------------
(Amounts in thousands)                                                                   First Quarter
                                                                             --------------------------------------
                                                                                 2000                      1999
                                                                                          (Unaudited)
------------------------------------------------------------------------------------------------------------------------------------

<S>                                                                           <C>                       <C>
Cash Flows From Operating Activities
       Net (loss) income.................................................   $    (255)                $     477
       Adjustments to reconcile net (loss) income to net
           cash flows provided by operating activities:
           Depreciation and amortization.................................         676                       337
           Changes in operating assets and liabilities:
                Accounts receivable......................................        (767)                   (1,295)
                Inventories..............................................       3,057                    (1,961)
                Other current assets.....................................      (1,198)                     (747)
                Accounts payable.........................................       3,008                     2,665
                Other current liabilities................................         670                      (945)
                                                                            ---------                 ---------

           Net cash flows provided by (used in)
           operating activities..........................................       5,191                    (1,469)
                                                                             --------                 ---------


Cash Flows From Investing Activities
       Equipment & leasehold improvements acquired.......................        (363)                   (1,534)
                                                                            ---------                 ---------

           Net cash flows used in investing activities...................        (363)                   (1,534)
                                                                            ---------                 ---------


Cash Flows From Financing Activities
       Sale of treasury stock............................................         890                        --
       Other, net........................................................         110                        13
                                                                            ---------                ----------
           Net cash flows provided by financing
                 activities..............................................       1,000                        13
                                                                            ---------                ----------

Increase (decrease) in cash..............................................       5,828                    (2,990)
Cash at beginning of period..............................................         744                     3,520
                                                                            ---------                 ---------

Cash at end of period....................................................   $   6,572                 $     530
                                                                            =========                 =========

------------------------------------------------------------------------------------------------------------------------------------

</TABLE>
The accompanying notes are an integral part of the financial statements.

                                       5
<PAGE>

MOORE MEDICAL CORP.

NOTES TO FINANCIAL STATEMENTS

Note 1 - Summary of Significant Accounting Policies

The Company

Moore Medical is a national marketer and distributor of healthcare products to
approximately 92,000 healthcare practitioner customers in non-hospital settings.
Primary customer groups are emergency medical services, medical departments at
industrial sites, physicians and podiatrists, and university/school health
services. It markets approximately 8,500 medical/surgical and pharmaceutical
supply products (SKUs) through direct mail, telesales, a small field sales force
and an early stage Internet company. The Company fulfills orders from its
strategically located regional distribution centers in Connecticut, Florida,
Illinois and California and ships orders nationwide by common carriers. The
Company has more than 50 years experience, and has served healthcare
practitioner customers for over 25 years.

Basis of Presentation

Moore Medical has prepared the accompanying unaudited financial statements in
accordance with generally accepted accounting principles for interim financial
statements. In the opinion of management, all adjustments necessary for a fair
presentation of the results for the interim period have been made. The results
for the three months ended April 1, 2000 do not necessarily indicate the results
to be expected for the fiscal year ended December 30, 2000 or any other future
period. The fiscal quarters ended on April 1, 2000 and April 3, 1999.

The accompanying unaudited financial statements should be read in conjunction
with the Notes to Financial Statements and Management's Discussion and Analysis
of Results of Operations and Financial Condition included in the Company's 1999
Annual Report filed on Form 10-K and in this Form 10-Q Report.

Note 2 - Contingencies

Beginning in 1991, the Company entered into various supply contracts with the
U.S. Department of Veterans Affairs and the Defense Department. In April 1997,
the Company completed a review of its compliance with various pricing provisions
of these contracts and, with the assistance of special legal counsel, concluded
that adjustments may be due to the federal agencies for potential unasserted
claims against the Company relating to pricing deficiencies under product supply
contracts subject to General Services Administration and Department of Defense
regulations. In the fourth

                                       6
<PAGE>

quarter of 1996, the Company established a $3.8 million reserve for estimated
pricing deficiency liabilities and associated legal costs. As of the end of 1999
and first quarter end of 2000, the reserve balance was $3.1 million. The final
amount of the pricing deficiency adjustment is subject to the outcome of
contract settlement discussions which the Company has requested with the
governmental agencies or to an adjudicated disposition. In management's opinion,
the ultimate resolution of this matter will not have a material adverse effect
on the Company's financial position. Although management believes that the
reserve is sufficient, it is possible the final resolution could exceed such
reserve and could have a material impact on the statement of operations and cash
flow in such period.

                                       7
<PAGE>

MOORE MEDICAL CORP.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        -----------------------------------------------------------------------
        OF OPERATIONS
        -------------

OVERVIEW
--------

Moore Medical's stated objective in our Form 10-K filed March 31, 2000
represents a strategic commitment to transforming the Company into a full
business to business electronic commerce enterprise. To accomplish this
objective we will continue to aggressively invest in technology, the acquisition
of customer communities and content, our operating platforms and other
e-business initiatives.

We are presently using our database to distinguish customers' buying patterns
and behaviors related to e-Commerce and our traditional business. Our investment
in the Internet is fundamental to our strategy and future sustainable growth. We
anticipate increased spending in an effort to acquire the talent and develop the
infrastructure needed to exploit this business opportunity.

The following table sets forth items included in the Statements of Operations as
a percentage of sales for the first quarter of 2000 and 1999. The table also
shows, for each line item, the percentage change of the amount in the 2000
period from the comparable 1999 period.

<TABLE>
<CAPTION>
                                                                                       First Quarter
                                                                   -------------------------------------------------------
                                                                              % of Sales                    % Change
                                                                   ---------------------------------    ------------------
                                                                        2000             1999
                                                                        ----             ----
<S>                                                                    <C>              <C>                    <C>
Net Sales.................................................             100.0%           100.0%                    2%
Cost of products sold.....................................              70.6             67.3                     7
                                                                     -------          -------
Gross profit..............................................              29.4             32.7                    (9)
Selling, general & administrative expenses................              30.8             30.3                     3
                                                                     -------          -------
Operating (loss) income...................................              (1.4)             2.4                  (161)
Interest (income), net....................................                --              (.1)                  (40)
                                                                     -------          -------
(Loss) /income before income taxes........................              (1.4)             2.5                  (154)
Income tax (benefit)  provision...........................              (0.5)              .9                  (155)
                                                                     -------          -------
Net (loss)  income........................................              (0.9)%            1.6%                 (153)%
                                                                     -------          -------
</TABLE>

                                       8
<PAGE>

RESULTS OF OPERATIONS
---------------------

Three Months Ended April 1, 2000 Compared to Three Months Ended April 3, 1999
-----------------------------------------------------------------------------

Overall, net revenue of $29.5 million for the first quarter of 2000 increased 2%
over the comparable period in 1999. Moore Medical experienced growth in its
business communities and e-Commerce. The favorable increase was partially offset
by the contraction of pharmaceutical product revenues. In the business
communities, the increase in net sales was primarily due to increased account
penetration with core dealer accounts. The remaining increase in the first
quarter 2000 net sales was due to increased e-Commerce activity on our
unpromoted transactional website, which increased $0.5 million or over 200%, to
$0.7 million for the three months ended April 1, 2000, from $0.2 million for the
three months ended April 3, 1999, while traffic has nearly doubled.

Gross profit decreased by $0.8 million, or 9% to $8.7 million for the three
months ended April 1, 2000, from $9.5 million for the three months ended April
3, 1999. The decrease is primarily attributable to the price erosion in
pharmaceutical products resulting in lower margins. Also, the Company's average
order size increased 13% over prior year, generating higher volume but at lower
margins.

Selling, general and administrative expenses increased by $0.3 million or 3%, to
$9.1 million for the first quarter 2000 from $8.8 million. The increase is
primarily due to higher depreciation charges associated with investments in
technology. Other contributing factors to the increase were additional media and
advertising costs associated with the acquisition of and intensive e-Commerce
marketing research of customers. We anticipate increased selling and marketing
expenses related to our Internet based business as a result of accelerated
spending to fully web enable the Company.

A net loss for the quarter of $(0.3) million or $(.09) earnings per share was
reported compared with net income of $0.5 million or $0.16 earnings per share in
the first quarter of 1999.

LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

On April 1, 2000, our unrestricted cash and cash equivalents totaled $6.6
million, a $5.9 million increase from a year ago. The increase was a result of
net cash flow provided by operating activities.

Our operations provided $5.2 million in cash during the three months ended April
1, 2000. Primary sources of cash were $3.1 million decrease in inventory levels,
$3.7 million increase in accounts payable and accrued liabilities driven by
successful supply

                                       9
<PAGE>

change management efforts. In addition, non-cash elements of $0.7 million
related to depreciation and amortization primarily related to technology
increased operating activities. Primary uses of cash included the net loss of
$0.3 million, an increase in accounts receivable driven by the increase in net
sales and $1.2 million in other assets.

Investing actitives used $0.4 million in the first quarter, primarily in
technology. Technology purchases were made to support our strategic commitment
to fully web enable the Company.

Financing activities provided $1.0 million in the first quarter, primarily
attributable to proceeds from the sales of treasury stock.

In our recent Annual Report on Form 10-K, we described our strategy to transform
the Company to a full business-to-business electronic commerce enterprise by
migrating existing customers and attracting additional customers to the new
comprehensive Internet platform we plan to launch. The Report noted that our
"Board recognizes the level of investment required to accomplish Moore's
Internet strategy." Management seeks to raise funds to transform our business
from institutional and other private equity sources. In addition, the Company's
previous line of credit expired on March 31, 2000, and management is currently
reviewing loan proposals. Management believes a definitive loan agreement, once
consummated, will provide adequate funds for the Company's operations. In the
interim, until a definitive loan agreement is negotiated and executed, the
Company had, as of March 31, 2000, $6.6 million in cash and cash equivalents to
fund its operations in the short term.

FORWARD-LOOKING INFORMATION
---------------------------

From time to time, the Company or its representatives may have made or may make
forward-looking statements, orally or in writing. Such forward-looking
statements may be included in, but, not limited to, press releases, oral
statements made by or with the approval of an authorized executive officer, or
in this report or other filings made by the Company with the Securities and
Exchange Commission. The words or phrases "trend," "expect," "grow," "will,"
"could," "likely result," "transform," "planned," "continued," "anticipated,"
"estimated," "believes," "continuing," "considers," "may be," "assessed,"
"contingency," "projected," "scheduled," "could have," "intended," or similar
expressions are intended to identify "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company
wishes to ensure that such statements are accompanied by meaningful cautionary
statements, so as to maximize to the fullest extent possible the protections of
the safe harbor established in the said Act. Accordingly, such statements are
qualified in their entirety by reference to

                                       10
<PAGE>

and are accompanied by the following discussion of certain important factors
that could cause actual results to differ materially from such forward-looking
statements.

Investors should be aware of factors that could have an impact on the Company's
business, financial position or performance. These include possible: pressures
on the Company's revenues resulting, for example, from customer consolidations
or changes in customer buying patterns; reductions in healthcare funding
affecting its customers' services or revenues, resulting, for example, from
changes in legislation or regulations or in HMO, managed care or other insurance
programs; intensified competition resulting, for example, from distributor
consolidations or pricing pressures from distributors able to benefit from
economies of scale or other operating efficiencies; and new Internet
unanticipated expenses, delays on technical problems associated with the
Company's planned Internet site; disruptions in services or systems on which the
Company is dependent, such as by truckers in deliveries from its suppliers, by
UPS or other common carriers in deliveries to its customers, by its catalog
printers or in telecommunication services, or relating to its computer systems
or; pending adjustments of pricing under exited government contracts or
unfavorable outcomes of litigation; and other factors detailed from time to time
in the Company's Securities and Exchange Commission filings or other readily
available or generally disseminated writings. The risks identified here are not
all inclusive. Reference is also made to other parts of this on Form 10-Q, which
include additional information concerning factors that could adversely impact
the Company's business or financial position or performance. Moreover, the
Company operates in a changing and very competitive business environment. New
risks may emerge from time to time, and it is not possible for management to
predict all risk factors, nor can it necessarily identify or assess the impact
of all such factors on the Company or the extent to which any factor or
combination of factors may cause actual results to differ materially from those
contained in any forward-looking statements. Accordingly, forward-looking
statements should not be relied upon as a prediction of actual results.

ITEM 3. Quantitative & Qualitative Disclosures About Market Risk
        --------------------------------------------------------

We have no material market risk exposure associated with activities in
derivative financial statements, other financial instruments, or derivative
commodity instruments.

                                       11
<PAGE>

PART II. OTHER INFORMATION
         -----------------

ITEM 5. OTHER MATTERS
        -------------

On March 1, 2000, Christopher W. Brody was elected to the Board of Directors of
the Company.

As of April 1, 2000, Moore Medical's Board of Directors is as follows:

              Name
              ----
              Linda M. Autore
              Robert H. Steele
              Steven Kotler
              Christopher W. Brody
              Peter C. Sutro
              Wilmer J. Thomas, Jr.
              Daniel K. Wassong


Item 6. Exhibits and Reports on Form 8-K
        --------------------------------

        (a)  Exhibits
             --------

             Employment Agreement between the Company             Exhibit 10.20
             and Linda M. Autore, effective March 1, 2000.

             Subscription Agreement between the Company           Exhibit 10.21
             and Vantage Venture Partners, LP, dated
             February 28, 2000.

             Website Development and Hosting Agreement            Exhibit 10.22
             between the Company and e-Media, LLC,
             dated January 21, 2000.

             Financial Data Schedule.                             Exhibit 27


        (b)  Reports on Form 8-K
             -------------------

             No report on Form 8-K was filed during the quarter.

                                       12
<PAGE>

                                   SIGNATURES
                                   ----------

     Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.


MOORE MEDICAL CORP.
(REGISTRANT)



By: /s/ Linda M. Autore                  By: /s/ Joseph P. Savidge
    ---------------------------------        -----------------------------------
     Linda M. Autore, President               Joseph P. Savidge, Senior
     And Chief Executive Officer              Vice President - Finance and
     May 15, 2000                             Chief Financial Officer
                                              May 15, 2000


                                         By: /s/ Susan G. D'Amato
                                             -----------------------------------
                                              Susan G. D'Amato, Vice President -
                                              Finance and Controller
                                              May 15, 2000

                                       13